Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;21(4):129-33.
doi: 10.5214/ans.0972.7531.210403.

Brain-Derived Neurotrophic Factor in Children With Autism Spectrum Disorder

Affiliations
Free PMC article

Brain-Derived Neurotrophic Factor in Children With Autism Spectrum Disorder

Nikhil J Kasarpalkar et al. Ann Neurosci. .
Free PMC article

Abstract

Background: Autism Spectrum Disorder (ASD) is a complex neurobehavioral syndrome with no known biomarker so far for early detection. It has been challenging, both to classify typical autism and associate a suitable biomarker with clinical phenotype spectrum. Brain-derived neurotrophic factor (BDNF) has emerged as a key neurotrophin regulating synaptic plasticity, neuronal differentiation and survival.

Purpose: Recently, BDNF depletion is reported in neurodegenerative as well as in psychiatric disorders, associated with severity of neurological dysfunction. Role of BDNF as a biomarker in ASD is gaining significance. Pre-clinical results have linked BDNF depletion in autism and mental retardation, however, with conflicting findings.

Methods: In view of this, a preliminary study was carried out to measure serum BDNF levels in 48 children with ASD and mental retardation, and 29 age-matched controls.

Results: Serum BDNF levels were found significantly higher (p<0.001) in atypical autistic subjects (clinically milder phenotype) as compared to controls, but not in typical ASD cases (clinically severe phenotype). BDNF levels were significantly lower in females with typical/Rett Syndrome (p<0.05), but not in males with typical autism (p>0.1), as compared to controls. Lower BDNF levels indicate impairment in neuroprotective mechanism, while higher levels may imply a manifested protective response.

Conclusion: Our study highlights the differential BDNF response based on the severity of neurobehavioral deficit, indicating a possible neuroprotective role of this molecule and supporting its exploration in targeted therapy in ASD.

Keywords: BDNF; Biomarker; Disorder.

Conflict of interest statement

Conflict of Interests: None: Source of funding: None.

Figures

Fig. 1:
Fig. 1:
Comparison of BDNF levels between Controls and ASD. As the spectrum of ASD presentation traverses from mild to a severe form, the BDNF response inversely correlates with decreasing values.

Similar articles

See all similar articles

Cited by 17 articles

See all "Cited by" articles

References

    1. Nelson K. Toward a biology of autism: possible role of certain neuropeptides and neurotrophins. Clin Neuro Res. 2001;1(4):300–306.
    1. Kanner L. Autistic disturbances of affective contact. Nervous Child. 1943;2:217–250.
    1. Filipek PA, Accardo PJ, Ashwal S et al. Practice parameter: Screening and diagnosis of autism: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology. 2000;55:468–479. - PubMed
    1. Centers for Disease Control and Prevention (CDC). Prevalence of — Autism Spectrum Disorders-Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States. 2002 - PubMed
    1. Centers for Disease Control and Prevention (CDC). Prevalence of —Autism Spectrum Disorders-Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States. 2002;MMWR SS 2007;56(No.SS-01):29–40. - PubMed

LinkOut - more resources

Feedback